Amphotericin B (1397-89-3)

Identification
Name:	Amphotericin B
Synonyms:	AmBiosone;Amphotericin .BETA.;Fungizone (TN);Fungizone;Amphozone;Amphotericin B,28,29-dihydro-;Ambisome;[1R-(1R,3S,5R,6R,9R,11R,15S,16R,17R,18S,19E,21E,23E,25E,27E,29E, 31E,33R,35S,36R,37S)]-33-[(3-Amino-3,6-dideoxy-.beta.-D- mannopyranosyl)oxy]-1,3,5,6,9,11,17,37-octahydroxy-15,16,18-;component of Talsutin;component of Mysteclin-F;Ampho-Moronal;Amphotericine B;(1R,3S,5S,8S,9S,11R,15S,16R,17R,18S,19E,21E,23E,25E,27E,29E,31E,33R,35S,36S,37S)-33-[(2S,3S,4S,5S,6R)-4-amino-3,5-dihydroxy-6-methyl-oxan-2-yl]oxy-1,3,5,8,9,11,17,37-octahydroxy-15,16,18-trimethyl-13-oxo-14,39-dioxabicyclo[33.3.1]nonatriaconta-19,21,23,25,27,29,31-heptaene-36-carboxylic acid;Mysteclin-F;(1R,3S,5R,6R,9R,11R,15S,16S,17R,18S,19E,21E,23E,25E,27E,29E,31E,33R,35S,36S,37S)-33-[(2S,3S,4S,5S,6R)-4-amino-3,5-dihydroxy-6-methyl-oxan-2-yl]oxy-1,3,5,6,9,11,17,37-octahydroxy-15,16,18-trimethyl-13-oxo-14,39-dioxabicyclo[33.3.1]nonatriaconta-19,21,23,25,27,29,31-heptaene-36-carboxylic acid;33-(4-amino-3,5-dihydroxy-6-methyl-oxan-2-yl)oxy-1,3,5,6,9,11,17,37-octahydroxy-15,16,18-trimethyl-13-oxo-14,39-dioxabicyclo[33.3.1]nonatriaconta-19,21,23,25,27,29,31-heptaene-36-carboxylic acid;Lipid nanosphere that incorporates amphotericin B;33-((3-amino-3,6-dideoxyhexopyranosyl)oxy)-1,3,5,6,9,11,17,37-octahydroxy-15,16,18-trimethyl-13-oxo-14,39-dioxabicyclo[33.3.1]nonatriaconta-19,21,23,25,27,29,31-heptaene-36-carboxylic acid;14,39-Dioxabicyclo[33.3.1]nonatriaconta-19,21,23,25,27,29, 31-heptaene-36-carboxylic acid, 33-[(3-amino-3, 6-dideoxy-.beta.-D-mannopyranosyl)oxy]-1,3,5,6,9,11,17, 37-octahydroxy-15,16,18-trimethyl-13-oxo-,[1R-(1R,3S,5R,6R, 9R,11R,15S,16R,17R,18S,19E,21E,23E,25E,27E,29E,31E,33R, 35S,36R,37S)]-;Liposomal Amphotericin B;Ribbon form of lipid-stabilized amphotericin B aggregates;Amphocin;Fungisone;Ambisome (TN);IAB;Amphotericin B (JP14/USP);AmB/LIPOSOMAL;(1R,3S,5R,6R,9R,11R,15S,16S,17R,18S,19E,21E,23E,25E,27E,29E,31E,33R,35S,36S,37S)-33-(4-amino-3,5-dihydroxy-6-methyl-oxan-2-yl)oxy-1,3,5,6,9,11,17,37-octahydroxy-15,16,18-trimethyl-13-oxo-14,39-dioxabicyclo[33.3.1]nonatriaconta-19,21,23,25,27,29,31-heptaene-36-carboxylic acid;(1R,3S,5R,6R,9R,11R,15S,16S,17R,18S,33R,35S,36S,37S)-33-[(2S,3S,4S,5S,6R)-4-amino-3,5-dihydroxy-6-methyl-oxan-2-yl]oxy-1,3,5,6,9,11,17,37-octahydroxy-15,16,18-trimethyl-13-oxo-14,39-dioxabicyclo[33.3.1]nonatriaconta-19,21,23,25,27,29,31-heptaene-36-carboxylic acid;AMPHOTERICIN B, STREPTOMYCES SPECIES;AMPHOMORONAL;NSC-527017;AMPHOTERICIN beta;IODOACETAMIDE;Amphotericin B (U.S. FDA Approved);Amphotericin B (for injection/oral);AmphotericcinB;8055-20-7;
CAS:	1397-89-3
EINECS:	215-742-2
Molecular Formula:	C47H73NO17
Molecular Weight:	924.08
InChI:	InChI=1/C47H73NO17/c1-27-17-15-13-11-9-7-5-6-8-10-12-14-16-18-34(64-46-44(58)41(48)43(57)30(4)63-46)24-38-40(45(59)60)37(54)26-47(61,65-38)25-33(51)22-36(53)35(52)20-19-31(49)21-32(50)23-39(55)62-29(3)28(2)42(27)56/h5-18,27-38,40-44,46,49-54,56-58,61H,19-26,48H2,1-4H3,(H,59,60)/b6-5+,9-7+,10-8+,13-11+,14-12+,17-15+,18-16+/t27-,28-,29-,30+,31+,32+,33-,34-,35+,36+,37-,38-,40+,41-,42+,43+,44-,46-,47+/m0/s1
Molecular Structure:
Properties
Transport:	UN 1759 8
Density:	1.34
Stability:	Stable, but may be light sensitive. Incompatible with strong oxidizing agents.
Refractive index:	1.614
Solubility:	<0.1 g/100 mL at 21 oC in water
Appearance:	Crystalline Yellow Solid
Specification:	Amphotericin B's Hazards Identification Inhalation:May cause respiratory tract irritation. May cause systemic effects. Skin:May cause skin irritation. Eyes:May cause eye irritation. Ingestion:May cause irritation of the digestive tract. Human fatalities have been reported from acute poisoning. May cause systemic effects.
Packinggroup:	III
Color:	yellow
Usage:	Polypeptide antibiotic active against gram positive bacteria. Antifungal.
Safety Data
Hazard Symbols	Xi:Irritant

Amphotericin B (1397-89-3)

Other Product